Global Recombinant Human Interleukin-2 for Injection Market Growth 2023-2029

February 2023 | 91 pages | ID: GBBD077514FBEN
LP Information

US$ 3,660.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The report requires updating with new data and is sent in 48 hours after order is placed.

Interleukin-2 is ia type of medication called a biologic response modifier. It is a type of protein called a cytokine that works to increase the production and function of some parts of your body's immune system.

LPI (LP Information)' newest research report, the “Recombinant Human Interleukin-2 for Injection Industry Forecast” looks at past sales and reviews total world Recombinant Human Interleukin-2 for Injection sales in 2022, providing a comprehensive analysis by region and market sector of projected Recombinant Human Interleukin-2 for Injection sales for 2023 through 2029. With Recombinant Human Interleukin-2 for Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Recombinant Human Interleukin-2 for Injection industry.

This Insight Report provides a comprehensive analysis of the global Recombinant Human Interleukin-2 for Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Recombinant Human Interleukin-2 for Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Recombinant Human Interleukin-2 for Injection market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Recombinant Human Interleukin-2 for Injection and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Recombinant Human Interleukin-2 for Injection.

The global Recombinant Human Interleukin-2 for Injection market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Recombinant Human Interleukin-2 for Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Recombinant Human Interleukin-2 for Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Recombinant Human Interleukin-2 for Injection is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Recombinant Human Interleukin-2 for Injection players cover Clinigen, 3SBio, Beijing Four Rings Biopharmaceutical, Jiangsu Kingsley Pharmaceutical, Beijing Yuance Pharmaceutical, Beijing SL Pharm, Shanghai Huaxin Biotechnology, Changchun Institute Of Biological Products and Shandong Quangang Pharmaceutical, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Recombinant Human Interleukin-2 for Injection market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type
  • 50000 IU
  • 100000 IU
  • 200000 IU
  • 500000 IU
  • 1 Million IU
Segmentation by application
  • Hospital
  • Pharmacy
This report also splits the market by region:
  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
  • Clinigen
  • 3SBio
  • Beijing Four Rings Biopharmaceutical
  • Jiangsu Kingsley Pharmaceutical
  • Beijing Yuance Pharmaceutical
  • Beijing SL Pharm
  • Shanghai Huaxin Biotechnology
  • Changchun Institute Of Biological Products
  • Shandong Quangang Pharmaceutical
Key Questions Addressed in this Report

What is the 10-year outlook for the global Recombinant Human Interleukin-2 for Injection market?

What factors are driving Recombinant Human Interleukin-2 for Injection market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Recombinant Human Interleukin-2 for Injection market opportunities vary by end market size?

How does Recombinant Human Interleukin-2 for Injection break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?
1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Recombinant Human Interleukin-2 for Injection Annual Sales 2018-2029
  2.1.2 World Current & Future Analysis for Recombinant Human Interleukin-2 for Injection by Geographic Region, 2018, 2022 & 2029
  2.1.3 World Current & Future Analysis for Recombinant Human Interleukin-2 for Injection by Country/Region, 2018, 2022 & 2029
2.2 Recombinant Human Interleukin-2 for Injection Segment by Type
  2.2.1 50000 IU
  2.2.2 100000 IU
  2.2.3 200000 IU
  2.2.4 500000 IU
  2.2.5 1 Million IU
2.3 Recombinant Human Interleukin-2 for Injection Sales by Type
  2.3.1 Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Type (2018-2023)
  2.3.2 Global Recombinant Human Interleukin-2 for Injection Revenue and Market Share by Type (2018-2023)
  2.3.3 Global Recombinant Human Interleukin-2 for Injection Sale Price by Type (2018-2023)
2.4 Recombinant Human Interleukin-2 for Injection Segment by Application
  2.4.1 Hospital
  2.4.2 Pharmacy
2.5 Recombinant Human Interleukin-2 for Injection Sales by Application
  2.5.1 Global Recombinant Human Interleukin-2 for Injection Sale Market Share by Application (2018-2023)
  2.5.2 Global Recombinant Human Interleukin-2 for Injection Revenue and Market Share by Application (2018-2023)
  2.5.3 Global Recombinant Human Interleukin-2 for Injection Sale Price by Application (2018-2023)

3 GLOBAL RECOMBINANT HUMAN INTERLEUKIN-2 FOR INJECTION BY COMPANY

3.1 Global Recombinant Human Interleukin-2 for Injection Breakdown Data by Company
  3.1.1 Global Recombinant Human Interleukin-2 for Injection Annual Sales by Company (2018-2023)
  3.1.2 Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Company (2018-2023)
3.2 Global Recombinant Human Interleukin-2 for Injection Annual Revenue by Company (2018-2023)
  3.2.1 Global Recombinant Human Interleukin-2 for Injection Revenue by Company (2018-2023)
  3.2.2 Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Company (2018-2023)
3.3 Global Recombinant Human Interleukin-2 for Injection Sale Price by Company
3.4 Key Manufacturers Recombinant Human Interleukin-2 for Injection Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Recombinant Human Interleukin-2 for Injection Product Location Distribution
  3.4.2 Players Recombinant Human Interleukin-2 for Injection Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR RECOMBINANT HUMAN INTERLEUKIN-2 FOR INJECTION BY GEOGRAPHIC REGION

4.1 World Historic Recombinant Human Interleukin-2 for Injection Market Size by Geographic Region (2018-2023)
  4.1.1 Global Recombinant Human Interleukin-2 for Injection Annual Sales by Geographic Region (2018-2023)
  4.1.2 Global Recombinant Human Interleukin-2 for Injection Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Recombinant Human Interleukin-2 for Injection Market Size by Country/Region (2018-2023)
  4.2.1 Global Recombinant Human Interleukin-2 for Injection Annual Sales by Country/Region (2018-2023)
  4.2.2 Global Recombinant Human Interleukin-2 for Injection Annual Revenue by Country/Region (2018-2023)
4.3 Americas Recombinant Human Interleukin-2 for Injection Sales Growth
4.4 APAC Recombinant Human Interleukin-2 for Injection Sales Growth
4.5 Europe Recombinant Human Interleukin-2 for Injection Sales Growth
4.6 Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales Growth

5 AMERICAS

5.1 Americas Recombinant Human Interleukin-2 for Injection Sales by Country
  5.1.1 Americas Recombinant Human Interleukin-2 for Injection Sales by Country (2018-2023)
  5.1.2 Americas Recombinant Human Interleukin-2 for Injection Revenue by Country (2018-2023)
5.2 Americas Recombinant Human Interleukin-2 for Injection Sales by Type
5.3 Americas Recombinant Human Interleukin-2 for Injection Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Recombinant Human Interleukin-2 for Injection Sales by Region
  6.1.1 APAC Recombinant Human Interleukin-2 for Injection Sales by Region (2018-2023)
  6.1.2 APAC Recombinant Human Interleukin-2 for Injection Revenue by Region (2018-2023)
6.2 APAC Recombinant Human Interleukin-2 for Injection Sales by Type
6.3 APAC Recombinant Human Interleukin-2 for Injection Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Recombinant Human Interleukin-2 for Injection by Country
  7.1.1 Europe Recombinant Human Interleukin-2 for Injection Sales by Country (2018-2023)
  7.1.2 Europe Recombinant Human Interleukin-2 for Injection Revenue by Country (2018-2023)
7.2 Europe Recombinant Human Interleukin-2 for Injection Sales by Type
7.3 Europe Recombinant Human Interleukin-2 for Injection Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Recombinant Human Interleukin-2 for Injection by Country
  8.1.1 Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales by Country (2018-2023)
  8.1.2 Middle East & Africa Recombinant Human Interleukin-2 for Injection Revenue by Country (2018-2023)
8.2 Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales by Type
8.3 Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Recombinant Human Interleukin-2 for Injection
10.3 Manufacturing Process Analysis of Recombinant Human Interleukin-2 for Injection
10.4 Industry Chain Structure of Recombinant Human Interleukin-2 for Injection

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Recombinant Human Interleukin-2 for Injection Distributors
11.3 Recombinant Human Interleukin-2 for Injection Customer

12 WORLD FORECAST REVIEW FOR RECOMBINANT HUMAN INTERLEUKIN-2 FOR INJECTION BY GEOGRAPHIC REGION

12.1 Global Recombinant Human Interleukin-2 for Injection Market Size Forecast by Region
  12.1.1 Global Recombinant Human Interleukin-2 for Injection Forecast by Region (2024-2029)
  12.1.2 Global Recombinant Human Interleukin-2 for Injection Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Recombinant Human Interleukin-2 for Injection Forecast by Type
12.7 Global Recombinant Human Interleukin-2 for Injection Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Clinigen
  13.1.1 Clinigen Company Information
  13.1.2 Clinigen Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.1.3 Clinigen Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.1.4 Clinigen Main Business Overview
  13.1.5 Clinigen Latest Developments
13.2 3SBio
  13.2.1 3SBio Company Information
  13.2.2 3SBio Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.2.3 3SBio Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.2.4 3SBio Main Business Overview
  13.2.5 3SBio Latest Developments
13.3 Beijing Four Rings Biopharmaceutical
  13.3.1 Beijing Four Rings Biopharmaceutical Company Information
  13.3.2 Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.3.3 Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.3.4 Beijing Four Rings Biopharmaceutical Main Business Overview
  13.3.5 Beijing Four Rings Biopharmaceutical Latest Developments
13.4 Jiangsu Kingsley Pharmaceutical
  13.4.1 Jiangsu Kingsley Pharmaceutical Company Information
  13.4.2 Jiangsu Kingsley Pharmaceutical Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.4.3 Jiangsu Kingsley Pharmaceutical Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.4.4 Jiangsu Kingsley Pharmaceutical Main Business Overview
  13.4.5 Jiangsu Kingsley Pharmaceutical Latest Developments
13.5 Beijing Yuance Pharmaceutical
  13.5.1 Beijing Yuance Pharmaceutical Company Information
  13.5.2 Beijing Yuance Pharmaceutical Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.5.3 Beijing Yuance Pharmaceutical Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.5.4 Beijing Yuance Pharmaceutical Main Business Overview
  13.5.5 Beijing Yuance Pharmaceutical Latest Developments
13.6 Beijing SL Pharm
  13.6.1 Beijing SL Pharm Company Information
  13.6.2 Beijing SL Pharm Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.6.3 Beijing SL Pharm Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.6.4 Beijing SL Pharm Main Business Overview
  13.6.5 Beijing SL Pharm Latest Developments
13.7 Shanghai Huaxin Biotechnology
  13.7.1 Shanghai Huaxin Biotechnology Company Information
  13.7.2 Shanghai Huaxin Biotechnology Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.7.3 Shanghai Huaxin Biotechnology Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.7.4 Shanghai Huaxin Biotechnology Main Business Overview
  13.7.5 Shanghai Huaxin Biotechnology Latest Developments
13.8 Changchun Institute Of Biological Products
  13.8.1 Changchun Institute Of Biological Products Company Information
  13.8.2 Changchun Institute Of Biological Products Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.8.3 Changchun Institute Of Biological Products Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.8.4 Changchun Institute Of Biological Products Main Business Overview
  13.8.5 Changchun Institute Of Biological Products Latest Developments
13.9 Shandong Quangang Pharmaceutical
  13.9.1 Shandong Quangang Pharmaceutical Company Information
  13.9.2 Shandong Quangang Pharmaceutical Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
  13.9.3 Shandong Quangang Pharmaceutical Recombinant Human Interleukin-2 for Injection Sales, Revenue, Price and Gross Margin (2018-2023)
  13.9.4 Shandong Quangang Pharmaceutical Main Business Overview
  13.9.5 Shandong Quangang Pharmaceutical Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES

Table 1. Recombinant Human Interleukin-2 for Injection Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Recombinant Human Interleukin-2 for Injection Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of 50000 IU
Table 4. Major Players of 100000 IU
Table 5. Major Players of 200000 IU
Table 6. Major Players of 500000 IU
Table 7. Major Players of 1 Million IU
Table 8. Global Recombinant Human Interleukin-2 for Injection Sales by Type (2018-2023) & (K Units)
Table 9. Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Type (2018-2023)
Table 10. Global Recombinant Human Interleukin-2 for Injection Revenue by Type (2018-2023) & ($ million)
Table 11. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Type (2018-2023)
Table 12. Global Recombinant Human Interleukin-2 for Injection Sale Price by Type (2018-2023) & (US$/Unit)
Table 13. Global Recombinant Human Interleukin-2 for Injection Sales by Application (2018-2023) & (K Units)
Table 14. Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Application (2018-2023)
Table 15. Global Recombinant Human Interleukin-2 for Injection Revenue by Application (2018-2023)
Table 16. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Application (2018-2023)
Table 17. Global Recombinant Human Interleukin-2 for Injection Sale Price by Application (2018-2023) & (US$/Unit)
Table 18. Global Recombinant Human Interleukin-2 for Injection Sales by Company (2018-2023) & (K Units)
Table 19. Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Company (2018-2023)
Table 20. Global Recombinant Human Interleukin-2 for Injection Revenue by Company (2018-2023) ($ Millions)
Table 21. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Company (2018-2023)
Table 22. Global Recombinant Human Interleukin-2 for Injection Sale Price by Company (2018-2023) & (US$/Unit)
Table 23. Key Manufacturers Recombinant Human Interleukin-2 for Injection Producing Area Distribution and Sales Area
Table 24. Players Recombinant Human Interleukin-2 for Injection Products Offered
Table 25. Recombinant Human Interleukin-2 for Injection Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 26. New Products and Potential Entrants
Table 27. Mergers & Acquisitions, Expansion
Table 28. Global Recombinant Human Interleukin-2 for Injection Sales by Geographic Region (2018-2023) & (K Units)
Table 29. Global Recombinant Human Interleukin-2 for Injection Sales Market Share Geographic Region (2018-2023)
Table 30. Global Recombinant Human Interleukin-2 for Injection Revenue by Geographic Region (2018-2023) & ($ millions)
Table 31. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Geographic Region (2018-2023)
Table 32. Global Recombinant Human Interleukin-2 for Injection Sales by Country/Region (2018-2023) & (K Units)
Table 33. Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Country/Region (2018-2023)
Table 34. Global Recombinant Human Interleukin-2 for Injection Revenue by Country/Region (2018-2023) & ($ millions)
Table 35. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Country/Region (2018-2023)
Table 36. Americas Recombinant Human Interleukin-2 for Injection Sales by Country (2018-2023) & (K Units)
Table 37. Americas Recombinant Human Interleukin-2 for Injection Sales Market Share by Country (2018-2023)
Table 38. Americas Recombinant Human Interleukin-2 for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 39. Americas Recombinant Human Interleukin-2 for Injection Revenue Market Share by Country (2018-2023)
Table 40. Americas Recombinant Human Interleukin-2 for Injection Sales by Type (2018-2023) & (K Units)
Table 41. Americas Recombinant Human Interleukin-2 for Injection Sales by Application (2018-2023) & (K Units)
Table 42. APAC Recombinant Human Interleukin-2 for Injection Sales by Region (2018-2023) & (K Units)
Table 43. APAC Recombinant Human Interleukin-2 for Injection Sales Market Share by Region (2018-2023)
Table 44. APAC Recombinant Human Interleukin-2 for Injection Revenue by Region (2018-2023) & ($ Millions)
Table 45. APAC Recombinant Human Interleukin-2 for Injection Revenue Market Share by Region (2018-2023)
Table 46. APAC Recombinant Human Interleukin-2 for Injection Sales by Type (2018-2023) & (K Units)
Table 47. APAC Recombinant Human Interleukin-2 for Injection Sales by Application (2018-2023) & (K Units)
Table 48. Europe Recombinant Human Interleukin-2 for Injection Sales by Country (2018-2023) & (K Units)
Table 49. Europe Recombinant Human Interleukin-2 for Injection Sales Market Share by Country (2018-2023)
Table 50. Europe Recombinant Human Interleukin-2 for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 51. Europe Recombinant Human Interleukin-2 for Injection Revenue Market Share by Country (2018-2023)
Table 52. Europe Recombinant Human Interleukin-2 for Injection Sales by Type (2018-2023) & (K Units)
Table 53. Europe Recombinant Human Interleukin-2 for Injection Sales by Application (2018-2023) & (K Units)
Table 54. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales by Country (2018-2023) & (K Units)
Table 55. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales Market Share by Country (2018-2023)
Table 56. Middle East & Africa Recombinant Human Interleukin-2 for Injection Revenue by Country (2018-2023) & ($ Millions)
Table 57. Middle East & Africa Recombinant Human Interleukin-2 for Injection Revenue Market Share by Country (2018-2023)
Table 58. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales by Type (2018-2023) & (K Units)
Table 59. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales by Application (2018-2023) & (K Units)
Table 60. Key Market Drivers & Growth Opportunities of Recombinant Human Interleukin-2 for Injection
Table 61. Key Market Challenges & Risks of Recombinant Human Interleukin-2 for Injection
Table 62. Key Industry Trends of Recombinant Human Interleukin-2 for Injection
Table 63. Recombinant Human Interleukin-2 for Injection Raw Material
Table 64. Key Suppliers of Raw Materials
Table 65. Recombinant Human Interleukin-2 for Injection Distributors List
Table 66. Recombinant Human Interleukin-2 for Injection Customer List
Table 67. Global Recombinant Human Interleukin-2 for Injection Sales Forecast by Region (2024-2029) & (K Units)
Table 68. Global Recombinant Human Interleukin-2 for Injection Revenue Forecast by Region (2024-2029) & ($ millions)
Table 69. Americas Recombinant Human Interleukin-2 for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 70. Americas Recombinant Human Interleukin-2 for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 71. APAC Recombinant Human Interleukin-2 for Injection Sales Forecast by Region (2024-2029) & (K Units)
Table 72. APAC Recombinant Human Interleukin-2 for Injection Revenue Forecast by Region (2024-2029) & ($ millions)
Table 73. Europe Recombinant Human Interleukin-2 for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Europe Recombinant Human Interleukin-2 for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales Forecast by Country (2024-2029) & (K Units)
Table 76. Middle East & Africa Recombinant Human Interleukin-2 for Injection Revenue Forecast by Country (2024-2029) & ($ millions)
Table 77. Global Recombinant Human Interleukin-2 for Injection Sales Forecast by Type (2024-2029) & (K Units)
Table 78. Global Recombinant Human Interleukin-2 for Injection Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 79. Global Recombinant Human Interleukin-2 for Injection Sales Forecast by Application (2024-2029) & (K Units)
Table 80. Global Recombinant Human Interleukin-2 for Injection Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 81. Clinigen Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 82. Clinigen Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 83. Clinigen Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 84. Clinigen Main Business
Table 85. Clinigen Latest Developments
Table 86. 3SBio Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 87. 3SBio Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 88. 3SBio Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 89. 3SBio Main Business
Table 90. 3SBio Latest Developments
Table 91. Beijing Four Rings Biopharmaceutical Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 92. Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 93. Beijing Four Rings Biopharmaceutical Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 94. Beijing Four Rings Biopharmaceutical Main Business
Table 95. Beijing Four Rings Biopharmaceutical Latest Developments
Table 96. Jiangsu Kingsley Pharmaceutical Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 97. Jiangsu Kingsley Pharmaceutical Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 98. Jiangsu Kingsley Pharmaceutical Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 99. Jiangsu Kingsley Pharmaceutical Main Business
Table 100. Jiangsu Kingsley Pharmaceutical Latest Developments
Table 101. Beijing Yuance Pharmaceutical Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 102. Beijing Yuance Pharmaceutical Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 103. Beijing Yuance Pharmaceutical Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 104. Beijing Yuance Pharmaceutical Main Business
Table 105. Beijing Yuance Pharmaceutical Latest Developments
Table 106. Beijing SL Pharm Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 107. Beijing SL Pharm Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 108. Beijing SL Pharm Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 109. Beijing SL Pharm Main Business
Table 110. Beijing SL Pharm Latest Developments
Table 111. Shanghai Huaxin Biotechnology Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 112. Shanghai Huaxin Biotechnology Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 113. Shanghai Huaxin Biotechnology Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 114. Shanghai Huaxin Biotechnology Main Business
Table 115. Shanghai Huaxin Biotechnology Latest Developments
Table 116. Changchun Institute Of Biological Products Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 117. Changchun Institute Of Biological Products Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 118. Changchun Institute Of Biological Products Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 119. Changchun Institute Of Biological Products Main Business
Table 120. Changchun Institute Of Biological Products Latest Developments
Table 121. Shandong Quangang Pharmaceutical Basic Information, Recombinant Human Interleukin-2 for Injection Manufacturing Base, Sales Area and Its Competitors
Table 122. Shandong Quangang Pharmaceutical Recombinant Human Interleukin-2 for Injection Product Portfolios and Specifications
Table 123. Shandong Quangang Pharmaceutical Recombinant Human Interleukin-2 for Injection Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 124. Shandong Quangang Pharmaceutical Main Business
Table 125. Shandong Quangang Pharmaceutical Latest Developments

LIST OF FIGURES

Figure 1. Picture of Recombinant Human Interleukin-2 for Injection
Figure 2. Recombinant Human Interleukin-2 for Injection Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Recombinant Human Interleukin-2 for Injection Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Recombinant Human Interleukin-2 for Injection Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Recombinant Human Interleukin-2 for Injection Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of 50000 IU
Figure 10. Product Picture of 100000 IU
Figure 11. Product Picture of 200000 IU
Figure 12. Product Picture of 500000 IU
Figure 13. Product Picture of 1 Million IU
Figure 14. Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Type in 2022
Figure 15. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Type (2018-2023)
Figure 16. Recombinant Human Interleukin-2 for Injection Consumed in Hospital
Figure 17. Global Recombinant Human Interleukin-2 for Injection Market: Hospital (2018-2023) & (K Units)
Figure 18. Recombinant Human Interleukin-2 for Injection Consumed in Pharmacy
Figure 19. Global Recombinant Human Interleukin-2 for Injection Market: Pharmacy (2018-2023) & (K Units)
Figure 20. Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Application (2022)
Figure 21. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Application in 2022
Figure 22. Recombinant Human Interleukin-2 for Injection Sales Market by Company in 2022 (K Units)
Figure 23. Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Company in 2022
Figure 24. Recombinant Human Interleukin-2 for Injection Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Company in 2022
Figure 26. Global Recombinant Human Interleukin-2 for Injection Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Recombinant Human Interleukin-2 for Injection Sales 2018-2023 (K Units)
Figure 29. Americas Recombinant Human Interleukin-2 for Injection Revenue 2018-2023 ($ Millions)
Figure 30. APAC Recombinant Human Interleukin-2 for Injection Sales 2018-2023 (K Units)
Figure 31. APAC Recombinant Human Interleukin-2 for Injection Revenue 2018-2023 ($ Millions)
Figure 32. Europe Recombinant Human Interleukin-2 for Injection Sales 2018-2023 (K Units)
Figure 33. Europe Recombinant Human Interleukin-2 for Injection Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Recombinant Human Interleukin-2 for Injection Revenue 2018-2023 ($ Millions)
Figure 36. Americas Recombinant Human Interleukin-2 for Injection Sales Market Share by Country in 2022
Figure 37. Americas Recombinant Human Interleukin-2 for Injection Revenue Market Share by Country in 2022
Figure 38. Americas Recombinant Human Interleukin-2 for Injection Sales Market Share by Type (2018-2023)
Figure 39. Americas Recombinant Human Interleukin-2 for Injection Sales Market Share by Application (2018-2023)
Figure 40. United States Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Recombinant Human Interleukin-2 for Injection Sales Market Share by Region in 2022
Figure 45. APAC Recombinant Human Interleukin-2 for Injection Revenue Market Share by Regions in 2022
Figure 46. APAC Recombinant Human Interleukin-2 for Injection Sales Market Share by Type (2018-2023)
Figure 47. APAC Recombinant Human Interleukin-2 for Injection Sales Market Share by Application (2018-2023)
Figure 48. China Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Recombinant Human Interleukin-2 for Injection Sales Market Share by Country in 2022
Figure 56. Europe Recombinant Human Interleukin-2 for Injection Revenue Market Share by Country in 2022
Figure 57. Europe Recombinant Human Interleukin-2 for Injection Sales Market Share by Type (2018-2023)
Figure 58. Europe Recombinant Human Interleukin-2 for Injection Sales Market Share by Application (2018-2023)
Figure 59. Germany Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Recombinant Human Interleukin-2 for Injection Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Recombinant Human Interleukin-2 for Injection Sales Market Share by Application (2018-2023)
Figure 68. Egypt Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Recombinant Human Interleukin-2 for Injection Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Recombinant Human Interleukin-2 for Injection in 2022
Figure 74. Manufacturing Process Analysis of Recombinant Human Interleukin-2 for Injection
Figure 75. Industry Chain Structure of Recombinant Human Interleukin-2 for Injection
Figure 76. Channels of Distribution
Figure 77. Global Recombinant Human Interleukin-2 for Injection Sales Market Forecast by Region (2024-2029)
Figure 78. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Recombinant Human Interleukin-2 for Injection Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Recombinant Human Interleukin-2 for Injection Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Recombinant Human Interleukin-2 for Injection Revenue Market Share Forecast by Application (2024-2029)


More Publications